PPARGC1A and Parkinson disease: Moreover, PPARγ agonist pioglitazone (an antidiabetic agent) and overexpression of PGC1-α were able to improve symptoms of amyotrophic lateral sclerosis in mouse models [377,378] and other PPARγ agonists can improve not only symptoms of neurodegenerative diseases (e.g., Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis), but also impaired cognitive functions, learning and memory [379,380].